Research map: First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

Back to the article

Papers in this map

  1. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification · Bruce D. Cheson · 2014 · 5729 citations · Cited by this paper
  2. Editorial: New molecular targets for personalized treatment for low-grade non-hodgkin lymphoma · Andrea Visentin · 2026 · Cites this paper
  3. Expansion and safety profile of CD28‐costimulated anti‐CD19 CAR T cells in B‐cell lymphoma versus autoimmune disease · 2026 · Related
  4. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells · Daniel W. Lee · 2018 · 3668 citations · Cited by this paper
  5. Publication Only · 2026 · Related
  6. Follicular Lymphoma International Prognostic Index · P. Solal-Celigny · 2004 · 1546 citations · Cited by this paper
  7. Polygenic scores in the diagnosis of abnormal complete blood count values · 2026 · Related
  8. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial · Mathias Rummel · 2013 · 1515 citations · Cited by this paper
  9. Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS) · 2026 · Related
  10. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study · Carla Casulo · 2015 · 864 citations · Cited by this paper
  11. From monoclonal to polyfunctional immunotherapy: Reprogramming CAR‐T‐cell therapy with oncolytic viruses in B‐cell malignancies · 2026 · Related
  12. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma · Robert E Marcus · 2017 · 812 citations · Cited by this paper
  13. Adult TWIST2 ‐high B‐ALL confirms metabolic association but reveals molecular heterogeneity · 2026 · Related
  14. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review · Bertrand Coiffier · 2008 · 798 citations · Cited by this paper
  15. Preclinical evaluation of the ROR1‐targeting antibody–drug conjugates zilovertamab vedotin and VLS‐211 against B‐cell ALL patient‐derived xenografts · 2026 · Related
  16. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. · Pauline Brice · 1997 · 650 citations · Cited by this paper
  17. Persistent BCR::ABL1 ‐positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome‐positive ALL · 2026 · Related
  18. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy · Bruce D. Cheson · 2016 · 522 citations · Cited by this paper
  19. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study · Ian W. Flinn · 2019 · 313 citations · Cited by this paper
  20. Mechanism of action of rituximab · Thomas Cerny · 2002 · 297 citations · Cited by this paper
  21. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing · Patrick J. Engelberts · 2020 · 179 citations · Cited by this paper
  22. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial · Jeremy S Abramson · 2024 · 176 citations · Cited by this paper
  23. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study · Kim Linton · 2024 · 166 citations · Cited by this paper
  24. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial · Judith Trotman · 2018 · 164 citations · Cited by this paper
  25. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy · Gloria Iacoboni · 2023 · 138 citations · Cited by this paper
  26. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment · Hilma J. van der Horst · 2021 · 101 citations · Cited by this paper
  27. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma · Franck Morschhauser · 2022 · 72 citations · Cited by this paper
  28. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Toby Andrew Eyre · 2025 · 72 citations · Cited by this paper
  29. Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis · Gemma K. Reynolds · 2024 · 51 citations · Cited by this paper
  30. Update on follicular lymphoma · Jonathan W. Friedberg · 2023 · 30 citations · Cited by this paper
  31. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial · Lorenzo Falchi · 2025 · 28 citations · Cited by this paper
  32. A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 · Andrew M. Evens · 2020 · 23 citations · Cited by this paper
  33. COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma · Victoria R. Nachar · 2023 · 12 citations · Cited by this paper
  34. Early Progressing Follicular Lymphoma · Danielle S. Wallace · 2021 · 10 citations · Cited by this paper
  35. Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival · Allison Marie Winter · 2018 · 10 citations · Cited by this paper
  36. Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma · Ciara Louise L. Freeman · 2018 · 8 citations · Cited by this paper
  37. Epigenetic targets in B- and T-cell lymphomas: latest developments · Marcelo Lima Ribeiro · 2023 · 7 citations · Cited by this paper
  38. Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study · Mariana Bastos‐Oreiro · 2024 · 7 citations · Cited by this paper
  39. Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial · Paolo Strati · 2025 · 7 citations · Cited by this paper

Source: OpenAlex (CC0)